IGFBP2 Is a Potential Master Regulator Driving the Dysregulated Gene Network Responsible for Short Survival in Glioblastoma Multiforme

Only 2% of glioblastoma multiforme (GBM) patients respond to standard therapy and survive beyond 36 months (long-term survivors, LTS), while the majority survive less than 12 months (short-term survivors, STS). To understand the mechanism leading to poor survival, we analyzed publicly available data...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalya, Manasa, Kel, Alexander, Wlochowitz, Darius, Wingender, Edgar, Beißbarth, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239365/
https://www.ncbi.nlm.nih.gov/pubmed/34211498
http://dx.doi.org/10.3389/fgene.2021.670240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239365/
https://www.ncbi.nlm.nih.gov/pubmed/34211498
http://dx.doi.org/10.3389/fgene.2021.670240

Ejemplares similares